Blood and tissue markers for liver cancer treatment response
Part of Cancer, Digestive system clinical trials.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- You are currently receiving or about to receive standard treatment for liver cancer, such as surgery, ablation, TACE, targeted therapy, or immunotherapy.
- You are expected to live at least 3 more months and are generally able to care for yourself (ECOG 0-2).
- Your liver function is mostly preserved (Child-Pugh class A or stable B).
- You agree to let researchers use your medical records, imaging, tissue samples, and blood samples from routine care. If extra blood is needed, you will be asked to sign a separate consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.